Washington is currently home to 1780 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Expanding Clinical Trial Awareness Among Black Communities Through Digital Engagement
NCT06218615
Recruiting
Under-representation of patients from racial/ethnic minority groups in cancer clinical trials is a major barrier to health equity. Black patients are significantly less likely to be enrolled in clinical trials compared with non-Hispanic White (White) patients although they carry a disproportionate burden of cancer mortality, the shortest survival rates, and are more likely to be diagnosed at later stages. Further, medical mistrust and lack of awareness and complexity of clinical trials are barri... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Cancer
Register for Updates
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
NCT06142383
Recruiting
This is a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Universal Research Group LLC Suite 202, Tacoma, Washington
Conditions: Heart Failure
Register for Updates
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet. The purpose of this study is to find out whether people with overweight or obesity who take a medicine called su... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Velocity Clinical Research, Seattle, Washington
Conditions: Obesity
Register for Updates
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
NCT06075745
Recruiting
This is a multi-center clinical trial in Cytomegalovirus (CMV) seronegative prospective liver transplant recipients to determine the efficacy of two doses of Cytomegalovirus-Modified Vaccinia Ankara (CMV-MVA) Triplex CMV vaccine pre-transplant. The primary objective is to assess the effect of pre-transplant (Tx) Triplex vaccination on duration of CMV antiviral therapy (AVT) within the first 100 days post-Tx in CMV seropositive donor (D+) and seronegative (R-) (D+R-) liver transplant recipients (... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Washington Medical Center: Transplantation, Seattle, Washington
Conditions: Liver Transplant
Register for Updates
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Rainier Clinical Research Center, Renton, Washington
Conditions: Obesity, Diabetes Mellitus, Type 2
Register for Updates
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Recruiting
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are: Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Register for Updates
IVIG for Infection Prevention After CAR-T-Cell Therapy
NCT05952804
Recruiting
This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's IgG... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Lymphoma
Register for Updates
Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer
NCT05911243
Recruiting
This clinical trial evaluates the feasibility and acceptability of acupressure to the ear (auricular) to address appetite and weight in patients with stage II-IV gastric, esophageal, or pancreatic cancer. Cancer anorexia, the abnormal loss of appetite, directly leads to cancer-associated weight loss (cachexia) through malnourishment, reduced caloric intake, treatment side-effects, and other modifiable risk factors. Cachexia prolongs length of hospital stay for patients, negatively impacts treatm... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/10/2024
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Register for Updates
Study of GS-4528 in Adults With Solid Tumors
NCT05840224
Recruiting
The goals of this clinical study are to identify if GS-4528 alone or in combination with anti-programmed cell death protein 1 (PD-1) (Anti-PD-1) Monoclonal Antibody is safe and tolerable in people with solid tumors and to identify the recommended dose of GS-4528 for further development that is safe to give to people alone or in combination with Anti-PD-1 Monoclonal Antibody. The primary objectives of this study are: To assess the safety and tolerability of GS-4528 as monotherapy and in combina... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: The University of Washington/FHCC, Seattle, Washington
Conditions: Solid Tumor
Register for Updates
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587
Recruiting
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
Register for Updates
Quantitative MRI Assessment of Breast Cancer Therapy Response
NCT05704062
Recruiting
The goal of this observational study is to investigate and validate multi-parametric magnetic resonance imaging (MRI) modalities for assessment of breast cancer response to neoadjuvant chemotherapy in a multi-site and multi-MRI scanner platform setting. This study is conducted at Oregon Health & Science University (OHSU), University of Washington (UW), and University of Iowa (UI) using Siemens, Philips, and General Electric MRI scanners, respectively. MRI is a type of scan that uses a very stron... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Washington, Seattle, Washington
Conditions: Breast Cancer
Register for Updates
A Study to Investigate LYL845 in Adults With Solid Tumors
NCT05573035
Recruiting
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
Register for Updates